Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Bicalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Bicalutamide SCHEMBL5365801 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1933417 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL3612 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (S)-Bicalutamide SCHEMBL29444530 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL28262190 | 0.98 | AR (0.96) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL679554 | 0.97 | AR (0.94) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL15325704 | 0.93 | AR (0.87) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4305206-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | Koninklijke Philips N.V. (NL) | 2024-01-17 | — | — | EP | disclosed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. | 2023-02-09 | — | — | US | disclosed |
| EP-4100075-A1 | IMPLANTABLE DRUG DELIVERY DEVICES FOR LOCALIZED DRUG DELIVERY | The Regents of University of California (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022189530-A1 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2022-09-15 | — | — | WO | disclosed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885ABCB11 4316/4885 |
| US-11273147-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885ABCB11 4316/4885 |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885ABCB11 4316/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885ABCB11 4316/4885 |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885CYP2C19 930/4885ABCB11 4150/4885 |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | AR 1/4885CYP2C19 1596/4885ABCB11 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.